TABLE 2

NOWS Outcomes and Adverse Events: FSMT Versus STMA Cohorts

NOWS Outcome and/or Adverse EventFSMTSTMAP
Secondary agent, n (%)3 of 48 (6)1 of 28 (4).63
LOS, d, median (IQR)17.0 (3.9)10.5 (10.5).003*
Opioid treatment d, median (IQR)11.7 (4.0)2.5 (9.0).0001*
Total mg of methadone, median (IQR)4.52 (4.31)0.53 (0.69)<.0001*
Readmissions within 30 d due to NOWS, n (%)1 of 48 (2)0 of 28 (0)>.99
Emergency department within 30 d, n (%)3 of 48 (6)2 of 28 (7)>.99
Seizures, n(%)0 of 48 (0)0 of 48 (0)
Transfers to higher levels of care, n (%)0 of 48 (0)0 of 48 (0)
  • STMA cohort includes all infants initiated on symptom-triggered methadone dosing, including those who failed STMA and were converted to fixed-schedule dosing. —, not applicable.

  • * P < .05.